Navigation Links
Watson Pharmaceuticals Reports Second Quarter 2008 Results
Date:8/6/2008

ed Statements of Cash Flows for the six months ended June 30, 2008 and 2007:

Table 3

Watson Pharmaceuticals, Inc.

Condensed Consolidated Statements of Cash Flows

(Unaudited; in thousands)

Six Months Ended

June 30,

2008 2007

Cash Flows from Operating Activities:

Net income $110,932 $68,021

Reconciliation to net cash provided

by operating activities:

Depreciation and amortization 84,508 125,613

Deferred income tax provision 17,363 (20,188)

Provision for inventory reserve 22,231 26,946

Restricted stock and stock option

compensation 9,256 6,910

Other adjustments (7,230) 2,034

Changes in assets and liabilities:

Accounts receivable, net (30,054) 86,090

Inventories (22,331) (67,980)

Accounts payable and accrued expense (18,912) (76,366)

Income taxes payable 5,145 18,058

Other assets and liabilities (4,722) 30,104

Total adjustments 55,254 131,221

Net cash provided by operating

activities 166,186 199,242

Cash Flows from Investing Activities:

Additions to property, equipment and

product rights (29,504) (35,
'/>"/>

SOURCE Watson Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17

Related biology technology :

1. Watson to Present at the Bear Stearns 20th Annual Healthcare Conference
2. Watson Receives FDA Approval for Generic Accuneb(R)
3. Warner Chilcott and Watson Pharmaceuticals Announce Launch of Tilia(TM) Fe
4. Watson to Present at the 2008 Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference
5. Watson Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Results; Provides 2008 Outlook
6. Barr Subsidiary Sues Watson for SEASONIQUE(R) Patent Infringement
7. Watson Files FDA Application for Generic LYBREL(R)
8. FDA Approves MIXJECT(TM), a Convenient, Easy-to-Use Drug Delivery System For Watson Pharmaceuticals TRELSTAR(R) DEPOT and TRELSTAR(R) LA
9. Cephalon Files Patent Infringement Lawsuit Against Watson Pharmaceuticals
10. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
11. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... 16, 2014 “Never say, ‘I ... Universität Marburg’s Department of Physics, advises young women ... newly released SPIE Women in Optics 18-month ... shy to ask questions.” , In the annual ... mathematics) occupations ranging from university professor and laboratory ...
(Date:12/17/2014)... BASKING RIDGE, N.J. (PRWEB) December 17, 2014 ... Ipsen (Euronext: IPN; ADR: IPSEY), ... 120 mg (referred to as Somatuline®) was approved ... for the treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETs) ... differentiated, locally advanced or metastatic disease to improve ...
(Date:12/17/2014)... This report is a professional ... For an overview analysis, the report introduces quartz ... structure, industry overview, policy analysis, and news analysis, ... has witnessed rapid development with key manufacturers increasing ... report mentions quartz tubing upstream raw materials and ...
(Date:12/17/2014)... December 17, 2014 Gene synthesis ... it has entered into a technology access and ... to apply DNA2.0’s proprietary protein engineering technology, known ... , “We are extremely excited that the global ... This proprietary bioengineering technology has now been ...
Breaking Biology Technology:Network, Multitask, Persevere: SPIE Women in Optics Planner Subjects Share from Experience 2Network, Multitask, Persevere: SPIE Women in Optics Planner Subjects Share from Experience 3Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 2Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 3Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 4Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 5Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 6Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 7Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 82020 Quartz Tubing Market: Global Development & Forecasts Analysis Now at DeepResearchReports.com 2ADM and DNA2.0 Enter Into Protein Engineering Technology Access and Service Agreement 2
... /PRNewswire-FirstCall/ - Oncothyreon Inc. (NASDAQ: ONTY ) (TSX: ONY) ... basic and diluted share, for the three months ended June 30, ... per basic and diluted share, for the comparable period in 2008. ... months ended June 30, 2009 for the change in the fair ...
... , , , ... Accera, Inc., a biotechnology company delivering breakthrough therapies in central ... paper in the peer-reviewed journal Nutrition & Metabolism . ... mild to moderate Alzheimer,s disease: a randomized, double-blind, placebo-controlled, multicenter ...
... , , , ... Cempra Pharmaceuticals today announced the appointment of John H. ... of Eli Lilly and Company, to the company,s Board of ... executive and operational management experience, including leadership of successful anti-infective ...
Cached Biology Technology:Oncothyreon reports second quarter 2009 financial results 2Oncothyreon reports second quarter 2009 financial results 3Oncothyreon reports second quarter 2009 financial results 4Oncothyreon reports second quarter 2009 financial results 5Oncothyreon reports second quarter 2009 financial results 6Oncothyreon reports second quarter 2009 financial results 7Accera Announces Peer-Reviewed Publication of the Results of its 90-Day Clinical Study of AC-1202 (Axona(TM) ) in Mild to Moderate Alzheimer's Disease 2Accera Announces Peer-Reviewed Publication of the Results of its 90-Day Clinical Study of AC-1202 (Axona(TM) ) in Mild to Moderate Alzheimer's Disease 3Cempra Pharmaceuticals Announces Appointment of John H. Johnson to Board of Directors 2Cempra Pharmaceuticals Announces Appointment of John H. Johnson to Board of Directors 3
(Date:12/11/2014)... 2014 Research and Markets ... ( http://www.researchandmarkets.com/research/9ql3kr/biometrics_market ) has announced the addition of ... report to their offering. One ... adoption of multimodal biometric systems. Multimodal biometric systems ... for verification and identification purposes. This helps to ...
(Date:12/10/2014)... , Dec. 8, 2014 You,ve been here before: ... but can,t remember your password, site key or the answer ... your first grade teacher? Today, Hoyos ... app that will finally put an end to the ... 1U TM . 1U leverages a user,s smartphone to ...
(Date:12/10/2014)... 2014 CIE San Diego has launched an ... connective tissue that enhances care coordination among social service ... client-level information; earned a second $1 million grant from ... seniors aging in community and; will be recognized as ... th 4-6p. CIE San Diego today ...
Breaking Biology News(10 mins):Biometrics Market in India 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 2The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 3Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 2Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 3Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 4
... Materials engineers have created a new type of membrane ... be used for environmental cleanup, water purification and industrial ... conventional filters for separating oil from water and works ... usually mutually exclusive. Researchers attached the material to a ...
... the Netherlands Royal Academy of Arts and Sciences (KNAW) ... a new research programme: the Joint Scientific Thematic Research ... and the Academy will work together on developing bilateral ... and the Academy launched the joint research programme during ...
... Journal of Preventive Medicine special issue on climate ... Climate Changing People" conference today in Los Angeles. ... MD, DrPH, speaking about the impacts of climate change ... public health challenge. Health professionals need to understand the ...
Cached Biology News:New filtering technology has environmental, industrial applications 2New filtering technology has environmental, industrial applications 3NWO and Academy launch research program with China 2Issues at intersection of climate change and health impact global well-being 2Issues at intersection of climate change and health impact global well-being 3Issues at intersection of climate change and health impact global well-being 4
... arrays have been developed for affinity ... A variety of ProteinChip chemical surfaces ... to their unique biochemical properties. Each ... side-by-side sample comparison, and the chips ...
... been developed for affinity capture of ... of ProteinChip chemical surfaces allow differential ... unique biochemical properties. Each chip has ... comparison, and the chips are color-coded ...
... have been developed for affinity capture ... variety of ProteinChip chemical surfaces allow ... their unique biochemical properties. Each chip ... sample comparison, and the chips are ...
... Gel extraction kit, 100 preps Storage: The kit ... For longer storage, keep all contents of the ... column purification kit utilizes a silica-gel based membrane ... fragments in the presence of specialized binding buffers. ...
Biology Products: